Distribution, teratogenicity, and embryonic delivered dose of retinoid Ro 23-9223

Toxicology and Applied Pharmacology

Volumn 164, Issue 2, 2000, Pages 171-175

  Willhite, Calvin C ^a,b   Lovey, Alan ^a,b   Eckhoff, Christian ^a,b  

^a STATE OF CALIFORNIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Distribution; Hamster; Placental transfer; Retinoid; Teratogenicity

Indexed keywords

ISOTRETINOIN; RETINOID; RO 23 9223; UNCLASSIFIED DRUG;

ACNE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG DISTRIBUTION; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; HAMSTER; NONHUMAN; PLACENTAL TRANSFER; PREGNANCY; TERATOGENICITY;

ANIMALIA; CRICETINAE;

EID: 0034656225     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8866     Document Type: Article

References (22)

1. Armstrong R. B., Ashenfelter K. O., Eckhoff C., Levin A. A., Shapiro S. S. General and reproductive toxicology of retinoids. Sporn M. B., Roberts A. B., Goodman D. S. The Retinoids, Biology, Chemistry and Medicine. 1994;545-572 Raven Press, New York.
2. Clewell H. J., Andersen M. E., Wills R. J., Latriano L. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J. Am. Acad. Dermatol. 36:1997;S77-S85.
3. Collins M. D., Tzimas G., Hummler H., Burgin H., Nau H. Comparative teratology and transplacental pharmacokinetics of all-trans-retinoic acid, 13-cis-retinoic acid, and retinyl palmitate following daily administrations in rats. Toxicol. Appl. Pharmacol. 127:1994;132-144.
4. Creech-Kraft J., Loefberg B., Chahoud I., Bochert G., Nau H. Teratogenicity and placental transfer of all-trans-, 13-cis-, 4-oxo-all-trans- and 4-oxo-13-cis-retinoic acid after administration of a low oral dose during organogenesis in mice. Toxicol. Appl. Pharmacol. 100:1989;162-176.
5. Eckhoff C., Chari S., Kromka M., Staudner H., Juhasz L., Rudiger H., Agnish N. Teratogenicity and transplacental pharmacokinetics of 13-cis-retinoic acid in rabbits. Toxicol. Appl. Pharmacol. 125:1994;34-41.
6. Eckhoff C., Willhite C. C. Embryonic delivered dose of isotretinoin (13-cis-retinoic acid) and its metabolites in hamsters. Toxicol. Appl. Pharmacol. 146:1997;79-87.
7. Evans R. M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
8. Gale J. B. Recent advances in the chemistry and biology of retinoids. Ellis G. P., Luscombe D. K. Progress in Medicinal Chemistry. 1993;1-55 Elsevier, New York.
9. Giguere V., Ong E. S., Segui P., Evans R. M. Identification of a receptor for the morphogen retinoic acid. Nature. 330:1987;624-629.
10. Leid M., Kastner P., Lyons R., Nakshatri H., Saunders M., Zacharewski T., Chen J. Y., Staub A., Garnier J., Sylvic M., Chambon P. Purification, cloning and RXR identity of the HeLa cell factor with which RAR and TR heterodimerize to bind target sequences efficiently. Cell. 68:1992;377-395.
11. Mangelsdorf D. J., Ong E. S., Dyck J. A., Evans R. M. A nuclear receptor that identifies a novel retinoic acid response pathway. Nature. 345:1990;224-229.
12. Orfanos C. E., Ehlert R., Gollnick H. The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs. 34:1987;459-503.
13. Peck G. L., Olsen T. G., Butkus D., Pandya M., Arnaud-Battandier J., Gross E. G., Windhorst D. B., Cheripko J. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J. Am. Acad. Dermatol. 6:1982;735-745.
14. Petkovich M., Brand N. J., Krust A., Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature. 330:1987;444-450.
15. Plewig G., Lunderschmidt C. Hamster ear sebaceous glands. J. Invest. Dermatol. 68:1977;171-176.
16. Rowland M., Tozer T. Clinical Pharmacokinetics. 1989;Dekker, New York.
17. Willhite C. C., Book S. A. The utility of disposition data in evaluating retinoid developmental toxicity. Abelson J. N., Simon M. I., Packer L. Methods in Enzymology. Retinoids. 1990;406-417 Academic Press, Orlando.
18. Willhite C. C., Clewell H. J. Physiologically-based pharmacokinetic scaling in retinoid developmental toxicity. Livrea M. Vitamin A and Retinoids. An Update of Biological Aspects and Clinical Applications. 1999;121-128 Birkhauser, Basel.
19. Willhite C. C., Shealy Y. F. Amelioration of embryotoxicity by structural modification of the terminal group of cancer chemopreventive retinoids. J. Natl. Cancer Inst. 72:1984;689-695.
20. Willhite C. C., Wier P. J., Berry D. L. Dose-response and structure-activity considerations in retinoid-induced dysmorphogenesis. CRC Crit. Rev. Toxicol. 20:1989;113-135.
21. Yu V. C., Delsert C., Andersen B., Holloway J. M., Devary O. V., Naar A. M., Kim S. Y., Boutin J. M., Glass C. K., Rosenfeld M. G. RXRβ: A coregulator that enhances binding of retinoic acid, thyroid hormone and vitamin D receptors to their cognate response element. Cell. 67:1991;1251-1266.
22. Zelent A., Krust A., Petkovich M., Kastner P., Chambon P. Cloning of murine α and β retinoic acid receptors and a novel receptor predominantly expressed in skin. Nature. 339:1989;714-717.